Combo treatment delays multiple myeloma progression and may improve survival, study finds

Article excerpt

A large international clinical trial found that patients with multiple myeloma who received a new immunotherapy combination lived significantly longer without their cancer progressing, with early signs suggesting improved overall survival. The combo treatment represents a potential advance for patients with this blood cancer, which currently affects tens of thousands globally. While the study shows promise, the researchers note that longer follow-up data will be needed to confirm survival benefits and determine how the treatment compares to existing standard-of-care options.